# Riccardo Valdagni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/67473/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 208<br>papers | 8,596<br>citations | 38660<br>50<br>h-index | 51492<br>86<br>g-index |
| 209<br>all docs | 209<br>docs citations | 209<br>times ranked | 11162<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181. | 0.6 | 2 |
| 2 | Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82. | 0.3 | 10 |
| 3 | Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67. | 0.2 | 13 |
| 4 | Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879. | 1.2 | 2 |
| 5 | A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancerâ€”Data from the International Multicenter Prospective PRIAS Study. European Urology Oncology, 2022, 5, 651-658. | 2.6 | 13 |
| 6 | Cross-cultural differences in men on active surveillanceâ€™ anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study. BMC Urology, 2022, 22, . | 0.6 | 0 |
| 7 | How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. Supportive Care in Cancer, 2021, 29, 645-651. | 1.0 | 8 |
| 8 | Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107. | 1.3 | 15 |
| 9 | How to implement the requirements of a quality assurance system for prostate cancer. World Journal of Urology, 2021, 39, 41-47. | 1.2 | 1 |
| 10 | Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers, 2021, 13, 2433. | 1.7 | 8 |
| 11 | Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiotherapy and Oncology, 2021, 158, 74-82. | 0.3 | 5 |
| 12 | Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243. | 1.7 | 2 |
| 13 | Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248. | 0.3 | 11 |
| 14 | Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. Journal of Urology, 2021, 206, 62-68. | 0.2 | 6 |
| 15 | Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: Analysis of the Italian branch of the REQUITE project. Radiologia Medica, 2021, 126, 1366-1373. | 4.7 | 17 |
| 16 | Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. Cancers, 2021, 13, 3983. | 1.7 | 1 |
| 17 | Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG 14300). Frontiers in Oncology, 2021, 11, 740661. | 1.3 | 4 |
| 18 | Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 2021, 34, 47-54. | 0.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300. Frontiers in Oncology, 2021, 11, 778729. | 1.3 | 1 |
| 20 | The role of individual characteristics in predicting decisional conflict for patients with prostate cancer (PCa): preliminary results. Current Psychology, 2020, 39, 354-363. | 1.7 | 0 |
| 21 | Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91. | 2.6 | 24 |
| 22 | Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study. Breast Journal, 2020, 26, 188-196. | 0.4 | 3 |
| 23 | EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250. | 0.9 | 132 |
| 24 | A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281. | 1.3 | 15 |
| 25 | Back to (new) normalityâ€"A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108. | 1.2 | 5 |
| 26 | Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300). Physica Medica, 2020, 76, 327-336. | 0.4 | 4 |
| 27 | The emerging role of PARP inhibitors in prostate cancer. Expert Review of Anticancer Therapy, 2020, 20, 715-726. | 1.1 | 12 |
| 28 | Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. Frontiers in Oncology, 2020, 10, 1207. | 1.3 | 7 |
| 29 | Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. Radiotherapy and Oncology, 2020, 147, 40-49. | 0.3 | 17 |
| 30 | SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. Cancers, 2020, 12, 1462. | 1.7 | 8 |
| 31 | miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. Cells, 2020, 9, 435. | 1.8 | 11 |
| 32 | ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861. | 2.0 | 29 |
| 33 | The simulation-CT: Radiotherapyâ€™s useful tool in the race against COVID-19 pandemic. A serendipity approach. Radiotherapy and Oncology, 2020, 147, 151-152. | 0.3 | 7 |
| 34 | External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909. | 1.3 | 1 |
| 35 | External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909. | 1.3 | 10 |
| 36 | Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societiesâ€™ agenda. Tumori, 2019, 105, 161-167. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta OncolÃ³gica, 2019, 58, 1757-1764. | 0.8 | 15 |
| 38 | Letter to the Editor. Contemporary Clinical Trials, 2019, 84, 105825. | 0.8 | 0 |
| 39 | Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncology, 2019, 99, 104453. | 0.8 | 43 |
| 40 | LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nature Communications, 2019, 10, 307. | 5.8 | 44 |
| 41 | REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67. | 0.3 | 53 |
| 42 | In Reply to Loganadane etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 103, 777-778. | 0.4 | 1 |
| 43 | Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery. Tumori, 2019, 105, 210-215. | 0.6 | 6 |
| 44 | The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. European Urology, 2019, 76, 179-186. | 0.9 | 15 |
| 45 | Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285. | 2.6 | 7 |
| 46 | miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCÎµ and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 51. | 3.5 | 64 |
| 47 | Making Active Surveillance a path towards health promotion: A qualitative study on prostate cancer patientsâ€™ perceptions of health promotion during Active Surveillance. European Journal of Cancer Care, 2019, 28, e13014. | 0.7 | 5 |
| 48 | Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336. | 2.6 | 8 |
| 49 | Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322. | 4.7 | 11 |
| 50 | Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. Medical Oncology, 2019, 36, 4. | 1.2 | 11 |
| 51 | Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531. | 0.9 | 58 |
| 52 | Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience. Clinical Breast Cancer, 2018, 18, e1059-e1066. | 1.1 | 9 |
| 53 | Texture analysis of T1â€w and T2â€w MR images allows a quantitative evaluation of radiationâ€induced changes of internal obturator muscles after radiotherapy for prostate cancer. Medical Physics, 2018, 45, 1518-1528. | 1.6 | 7 |
| 54 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211. | 0.9 | 488 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Quality of life in active surveillance and the associations with decision-makingâ€"a literature review. Translational Andrology and Urology, 2018, 7, 160-169. | 0.6 | 8 |
| 56 | Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272. | 0.8 | 26 |
| 57 | Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1533-1542. | 0.4 | 14 |
| 58 | Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 127-136. | 0.4 | 14 |
| 59 | Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. Disease Markers, 2018, 2018, 1-9. | 0.6 | 13 |
| 60 | Equipment, staffing, and provision of radiotherapy in Lombardy, Italy: Results of three surveys performed between 2012 and 2016. Tumori, 2018, 104, 352-360. | 0.6 | 8 |
| 61 | Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. Tumori, 2018, 104, 172-178. | 0.6 | 5 |
| 62 | Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. Medical Oncology, 2018, 35, 107. | 1.2 | 8 |
| 63 | Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. Clinical Breast Cancer, 2018, 18, e363-e371. | 1.1 | 14 |
| 64 | Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Translational Andrology and Urology, 2018, 7, 98-105. | 0.6 | 24 |
| 65 | Better-Informed Decision-Making to Optimize Patient Selection. Current Clinical Urology, 2018, , 149-167. | 0.0 | 2 |
| 66 | Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendationsâ€"A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655. | 0.9 | 190 |
| 67 | miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Letters, 2017, 395, 53-62. | 3.2 | 80 |
| 68 | Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey. Radiologia Medica, 2017, 122, 140-145. | 4.7 | 4 |
| 69 | Management of metastatic castration-resistant prostate cancer: A focus on radium-223. Critical Reviews in Oncology/Hematology, 2017, 113, 43-51. | 2.0 | 28 |
| 70 | Semantics in active surveillance for men with localized prostate cancer â€" results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322. | 1.9 | 65 |
| 71 | Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions. Journal of Geriatric Oncology, 2017, 8, 289-295. | 0.5 | 14 |
| 72 | Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the doseâ€"effect. Radiotherapy and Oncology, 2017, 125, 101-106. | 0.3 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel doseâ€“volume effects. Radiotherapy and Oncology, 2017, 124, 296-301. | 0.3 | 26 |
| 74 | Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology, 2017, 71, 274-280. | 0.9 | 11 |
| 75 | An Accurate Method to Quantify Breathing-induced Prostate Motion for Patients Implanted with Electromagnetic Transponders. Tumori, 2017, 103, 136-142. | 0.6 | 1 |
| 76 | Phase II Multi-institutional Clinical Trial on a New Mixed Beam RT Scheme of IMRT on Pelvis Combined with a Carbon Ion Boost for High-risk Prostate Cancer Patients. Tumori, 2017, 103, 314-318. | 0.6 | 12 |
| 77 | Physicists' Views on Hadrontherapy: A Survey of Members of the Italian Association of Medical Physics (AIFM). Tumori, 2017, 103, 430-437. | 0.6 | 0 |
| 78 | Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. Tumori, 2017, 103, 292-298. | 0.6 | 1 |
| 79 | Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. Tumori, 2017, 103, 395-404. | 0.6 | 20 |
| 80 | Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. Tumori, 2017, 103, 464-474. | 0.6 | 20 |
| 81 | Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget, 2017, 8, 10919-10930. | 0.8 | 17 |
| 82 | Multidisciplinary Approach of Prostate Cancer Patients. , 2017, , 281-293. | | 0 |
| 83 | Comment on â€œObjective assessment in digital images of skin erythema caused by radiotherapyâ€•[Med. Phys. 42, 5568-5577 (2015)]. Medical Physics, 2016, 43, 2687-2688. | 1.6 | 4 |
| 84 | Predicting toxicity in radiotherapy for prostate cancer. Physica Medica, 2016, 32, 521-532. | 0.4 | 75 |
| 85 | Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. European Journal of Cancer, 2016, 67, 91-98. | 1.3 | 17 |
| 86 | Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Therapeutic Advances in Medical Oncology, 2016, 8, 323-330. | 1.4 | 13 |
| 87 | Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2016, 108, 13-22. | 2.0 | 30 |
| 88 | â€œWhat ifâ€¦â€• Decisional Regret in Patients who Discontinued Active Surveillance. Tumori, 2016, 102, 562-568. | 0.6 | 6 |
| 89 | A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. European Urology, 2016, 70, 954-960. | 0.9 | 290 |
| 90 | Baseline status and dose to the penile bulb predict impotence 1Âyear after radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 297-304. | 1.0 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. BJU International, 2016, 118, 366-371. | 1.3 | 51 |
| 92 | Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 118, 92-98. | 0.3 | 22 |
| 93 | Estimates of prostate cancer burden in Italy. Cancer Epidemiology, 2016, 40, 166-172. | 0.8 | 10 |
| 94 | First application of a pixel-wise analysis on bladder doseâ€“surface maps in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 119, 123-128. | 0.3 | 47 |
| 95 | Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nature Reviews Urology, 2016, 13, 151-167. | 1.9 | 139 |
| 96 | Involving a Citizensâ€™ Jury in Decisions on Individual Screening for Prostate Cancer. PLoS ONE, 2016, 11, e0143176. | 1.1 | 10 |
| 97 | PD34-04 FREQUENCY OF PSA TESTING IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER.. Journal of Urology, 2015, 193, . | 0.2 | 3 |
| 98 | Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 479-482. | 0.6 | 26 |
| 99 | Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. Tumori, 2015, 101, 174-178. | 0.6 | 9 |
| 100 | High quality surface reconstruction in radiotherapy: Cross-sectional contours to 3D mesh using wavelets. , 2015, 2015, 4222-5. | | 5 |
| 101 | Active Surveillance for Low-risk Prostate Cancer: Developments to Date. European Urology, 2015, 67, 646-648. | 0.9 | 25 |
| 102 | How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. European Urology, 2015, 67, 637-645. | 0.9 | 105 |
| 103 | Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Critical Reviews in Oncology/Hematology, 2015, 95, 133-143. | 2.0 | 23 |
| 104 | Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. European Urology, 2015, 68, 814-821. | 0.9 | 116 |
| 105 | Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World Journal of Urology, 2015, 33, 1735-1740. | 1.2 | 7 |
| 106 | Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunology Letters, 2015, 168, 105-110. | 1.1 | 11 |
| 107 | Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. Radiotherapy and Oncology, 2015, 116, 185-191. | 0.3 | 29 |
| 108 | Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget, 2015, 6, 31441-31460. | 0.8 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Editorial Comment to Healthâ€related quality of life after carbonâ€ion radiotherapy for prostate cancer: A 3â€year prospective study. International Journal of Urology, 2014, 21, 375-376. | 0.5 | 0 |
| 110 | Living with untreated prostate cancer. Current Opinion in Urology, 2014, 24, 311-317. | 0.9 | 10 |
| 111 | Long term rectal function after high-dose prostatecancer radiotherapy: Results from a prospective cohort study. Radiotherapy and Oncology, 2014, 110, 272-277. | 0.3 | 30 |
| 112 | Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 518-524. | 0.4 | 29 |
| 113 | miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. Antioxidants and Redox Signaling, 2014, 20, 1045-1059. | 2.5 | 63 |
| 114 | Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499. | 0.9 | 195 |
| 115 | Can we improve the definition of highâ€risk, hormone naÃ¯ve, nonâ€metastatic prostate cancer?. BJU International, 2014, 113, 189-199. | 1.3 | 11 |
| 116 | The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. Clinical Oncology, 2014, 26, 739-742. | 0.6 | 73 |
| 117 | miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539. | 3.5 | 40 |
| 118 | miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochemical Pharmacology, 2014, 87, 579-597. | 2.0 | 83 |
| 119 | Relationships between bladder doseâ€“volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2014, 111, 100-105. | 0.3 | 43 |
| 120 | Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status. PLoS ONE, 2014, 9, e86659. | 1.1 | 10 |
| 121 | â€˜Act on Oncologyâ€™ as a New Comprehensive Approach to Assess Prostate Cancer Centres â€“ Method Description and Results of a Pilot Study. PLoS ONE, 2014, 9, e106743. | 1.1 | 4 |
| 122 | Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology, 2013, 63, 597-603. | 0.9 | 450 |
| 123 | Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162. | 0.6 | 137 |
| 124 | Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. Eur Urol 2013;64:37â€“9. European Urology, 2013, 64, 39-40. | 0.9 | 1 |
| 125 | Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology, 2013, 85, 295-302. | 2.0 | 46 |
| 126 | Reducing rectal injury during external beam radiotherapy for prostate cancer. Nature Reviews Urology, 2013, 10, 345-357. | 1.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. European Urology, 2013, 64, 30-36. | 0.9 | 81 |
| 128 | Impact of the radiotherapy technique on the correlation between doseâ€“volume histograms of the bladder wall defined on MRI imaging and doseâ€“volume/surface histograms in prostate cancer patients. Physics in Medicine and Biology, 2013, 58, N115-N123. | 1.6 | 12 |
| 129 | Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. Journal of Applied Clinical Medical Physics, 2013, 14, 162-172. | 0.8 | 19 |
| 130 | Don't run before you can walk. Nature Reviews Urology, 2012, 9, 602-602. | 1.9 | 0 |
| 131 | Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. Physics in Medicine and Biology, 2012, 57, 1399-1412. | 1.6 | 44 |
| 132 | Is It Time to Tailor the Prediction of Radio-Induced Toxicity in Prostate Cancer Patients? Building the First Set of Nomograms for Late Rectal Syndrome. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1957-1966. | 0.4 | 41 |
| 133 | Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. International Journal of Radiation Oncology Biology Physics, 2012, 83, 38-45. | 0.4 | 38 |
| 134 | Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. International Journal of Radiation Oncology Biology Physics, 2012, 84, 841-846. | 0.4 | 41 |
| 135 | Correlation between surrogates of bladder dosimetry and doseâ€“volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. Radiotherapy and Oncology, 2012, 105, 180-183. | 0.3 | 18 |
| 136 | Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial. Radiotherapy and Oncology, 2012, 103, 252-255. | 0.3 | 39 |
| 137 | miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death and Differentiation, 2012, 19, 1750-1760. | 5.0 | 77 |
| 138 | Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance Program. European Urology, 2012, 61, 370-377. | 0.9 | 64 |
| 139 | Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. European Urology, 2012, 62, 195-200. | 0.9 | 89 |
| 140 | The 6â€year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU International, 2012, 110, 998-1003. | 1.3 | 47 |
| 141 | Patientâ€™s choice of observational strategy for early-stage prostate cancer. Neuropsychological Trends (discontinued), 2012, , . | 0.4 | 8 |
| 142 | The requirements of a specialist Prostate Cancer Unit: A discussion paper from the European School of Oncology. European Journal of Cancer, 2011, 47, 1-7. | 1.3 | 45 |
| 143 | Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 100, 124-130. | 0.3 | 65 |
| 144 | Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between lowâ€“intermediate and high risk patients. Radiotherapy and Oncology, 2011, 101, 454-459. | 0.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU International, 2011, 108, 223-227. | 1.3 | 10 |
| 146 | Prostate Cancer Units: Has the Time Come to Discuss This Thorny Issue and Promote their Establishment in Europe?. European Urology, 2011, 60, 1193-1196. | 0.9 | 8 |
| 147 | Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. Radiation Oncology, 2011, 6, 123. | 1.2 | 17 |
| 148 | Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. Journal of Oncology Practice, 2011, 7, e1-e5. | 2.5 | 27 |
| 149 | Shortâ€term outcomes of the prospective multicentre â€˜Prostate Cancer Research International: Active Surveillanceâ€™ study. BJU International, 2010, 105, 956-962. | 1.3 | 157 |
| 150 | miR-21: an oncomir on strike in prostate cancer. Molecular Cancer, 2010, 9, 12. | 7.9 | 189 |
| 151 | Multipeptide vaccination in cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 1043-1055. | 1.4 | 57 |
| 152 | Prostate cancer treatment in Europe at the end of 1990s. Acta OncolÃ³gica, 2009, 48, 867-873. | 0.8 | 11 |
| 153 | miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cĵµ. Cancer Research, 2009, 69, 2287-2295. | 0.4 | 334 |
| 154 | The 2008 European School of Oncology inside Track Conference, â€œPredictive Modeling in Prostate Cancerâ€• Cancer, 2009, 115, 3035-3038. | 2.0 | 2 |
| 155 | Predictive models of toxicity in external radiotherapy. Cancer, 2009, 115, 3135-3140. | 2.0 | 39 |
| 156 | Predictive models of toxicity with external radiotherapy for prostate cancer. Cancer, 2009, 115, 3141-3149. | 2.0 | 33 |
| 157 | Phase Iâ€“II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 392-398. | 0.4 | 58 |
| 158 | Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. Cancer Immunology, Immunotherapy, 2009, 58, 1159-1167. | 2.0 | 21 |
| 159 | Quality assurance of 3D-CRT: Indications and difficulties in their applications. Critical Reviews in Oncology/Hematology, 2009, 70, 24-38. | 2.0 | 9 |
| 160 | To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Doseâ€“Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440. | 0.4 | 55 |
| 161 | Doseâ€“volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology, 2009, 93, 153-167. | 0.3 | 249 |
| 162 | Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. Radiotherapy and Oncology, 2009, 93, 197-202. | 0.3 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Predictive Modeling in Prostate Cancer: A Conference Summary. European Urology, 2009, 55, 300-302. | 0.9 | 3 |
| 164 | Clinical and Dosimetric Predictors of Late Rectal Syndrome After 3D-CRT for Localized Prostate Cancer: Preliminary Results of a Multicenter Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1130-1137. | 0.4 | 132 |
| 165 | Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1065-1073. | 0.4 | 68 |
| 166 | Evidence of Limited Motion of the Prostate by Carefully Emptying the Rectum as Assessed by Daily MVCT Image Guidance with Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 611-617. | 0.4 | 71 |
| 167 | Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase Iâ€“II study. Radiotherapy and Oncology, 2008, 88, 26-33. | 0.3 | 39 |
| 168 | Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. Acta OncolÃ³gica, 2008, 47, 1309-1316. | 0.8 | 35 |
| 169 | Regional Estimates of Prostate Cancer Burden in Italy. Tumori, 2007, 93, 380-386. | 0.6 | 25 |
| 170 | Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1401-1410. | 0.4 | 91 |
| 171 | Vaccination therapy in prostate cancer. Cancer Immunology, Immunotherapy, 2007, 56, 429-445. | 2.0 | 21 |
| 172 | Emptying the rectum before treatment delivery limits the variations of rectal doseâ€“volume parameters during 3DCRT of prostate cancer. Radiotherapy and Oncology, 2006, 80, 363-370. | 0.3 | 74 |
| 173 | Fractionation and late rectal toxicity: No reliable estimates of Î±/Î² value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: In regard to Brenner (Int J Radiat Oncol Biol Phys 2004;60:1013â€“1015.). International Journal of Radiation Oncology Biology Physics, 2005, 62, 289-290. | 0.4 | 6 |
| 174 | In regard to Kagan: â€œThe multidisciplinary clinicâ€•(Int J Radiat Oncol Biol Phys 2005;61:967â€“968). International Journal of Radiation Oncology Biology Physics, 2005, 63, 309-310. | 0.4 | 13 |
| 175 | Cancer of the prostate. Critical Reviews in Oncology/Hematology, 2005, 56, 379-396. | 2.0 | 89 |
| 176 | Italian Survey in Postoperative Radiation Therapy for Prostate Carcinoma by the Airo National Working Group on Prostate Radiotherapy: Definitive Results. Tumori, 2005, 91, 156-162. | 0.6 | 1 |
| 177 | Is the alphaâ€“beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiotherapy and Oncology, 2005, 75, 74-82. | 0.3 | 74 |
| 178 | In response to Dr. G. Bauman and Dr. G. Rodrigues. International Journal of Radiation Oncology Biology Physics, 2004, 59, 914-915. | 0.4 | 0 |
| 179 | Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiotherapy and Oncology, 2004, 73, 21-32. | 0.3 | 183 |
| 180 | The impact of contouring uncertainty on rectal 3D doseâ€“volume data: Results of a dummy run in a multicenter trial (AIROPROS01â€“02). International Journal of Radiation Oncology Biology Physics, 2003, 57, 573-579. | 0.4 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Rectal doseâ€“volume constraints in high-dose radiotherapy of localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 57, 953-962. | 0.4 | 177 |
| 182 | Malignant melanoma. Critical Reviews in Oncology/Hematology, 2003, 47, 35-63. | 2.0 | 55 |
| 183 | Subclinical Ductal Carcinoma in Situ of the Breast: Treatment with Conservative Surgery and Radiotherapy. Tumori, 1999, 85, 488-493. | 0.6 | 11 |
| 184 | Patterns of radiotherapy for early breast cancer in Northern Italy compared with European and national standards. Radiotherapy and Oncology, 1999, 51, 79-85. | 0.3 | 10 |
| 185 | Quality Control by Portal Film Analysis in Radiotherapy for Prostate Cancer: A Comparison between Two Different Institutions and Treatment Techniques. Tumori, 1998, 84, 640-648. | 0.6 | 5 |
| 186 | Hyperfractionated radiation in combination with local hyperthermia in the treatment of advanced squamous cell carcinoma of the head and neck: a phase Iâ€“II study. Radiotherapy and Oncology, 1997, 45, 155-158. | 0.3 | 24 |
| 187 | Clinical target volume localization using conventional methods (anatomy and palpation) and ultrasonography in early breast cancer post-operative external irradiation. Radiotherapy and Oncology, 1997, 42, 231-237. | 0.3 | 14 |
| 188 | Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. European Journal of Cancer, 1997, 33, 1559-1565. | 1.3 | 35 |
| 189 | Past and present of radiation oncology in Italy. International Journal of Radiation Oncology Biology Physics, 1996, 35, 609-614. | 0.4 | 0 |
| 190 | Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer, 1995, 75, 908-913. | 2.0 | 22 |
| 191 | Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients. International Journal of Radiation Oncology Biology Physics, 1994, 28, 163-169. | 0.4 | 263 |
| 192 | Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: A phase Iâ€“II study. International Journal of Radiation Oncology Biology Physics, 1993, 26, 801-807. | 0.4 | 59 |
| 193 | Beam modifying devices in the treatment of early breast cancer: 3-D stepped compensating technique. Radiotherapy and Oncology, 1992, 23, 192-195. | 0.3 | 19 |
| 194 | Radiation Treatment of Prostate Bone Metastases and the Biological Considerations. Advances in Experimental Medicine and Biology, 1992, 324, 255-268. | 0.8 | 8 |
| 195 | Quality control in the conservative treatment of breast cancer: patient dosimetry using silicon detectors. Radiotherapy and Oncology, 1991, 22, 304-307. | 0.3 | 9 |
| 196 | Early breast cancer irradiation after conservative surgery: quality control by portal localization films. Radiotherapy and Oncology, 1991, 22, 311-313. | 0.3 | 31 |
| 197 | Response to Parsons. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1382. | 0.4 | 1 |
| 198 | Radiation Therapy of Carotid Body Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 1990, 13, 45-48. | 0.6 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Reduction of spinal metastases after preemptive irradiation in prostatic cancer. International Journal of Radiation Oncology Biology Physics, 1990, 18, 1019-1025. | 0.4 | 16 |
| 200 | Evaluating Radiation in Combination with Hyperthermia Trials: The Importance of Clinical and Technical Parameters. Tumori, 1990, 76, 205-211. | 0.6 | 1 |
| 201 | Absorption rate density (ARD) computation in microwave hyperthermia by the finite-difference time-domain method. Physics in Medicine and Biology, 1990, 35, 891-904. | 1.6 | 5 |
| 202 | Important prognostic factors influencing outcome of combined radiation and hyperthermia. International Journal of Radiation Oncology Biology Physics, 1988, 15, 959-972. | 0.4 | 102 |
| 203 | Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: a prospective randomized clinical trial. International Journal of Radiation Oncology Biology Physics, 1988, 15, 13-24. | 0.4 | 156 |
| 204 | Intracavitary hyperthermia: Construction and heat patterns of individualized vaginal prototype applicators. International Journal of Hyperthermia, 1988, 4, 457-466. | 1.1 | 17 |
| 205 | Peripheral DTIC neurotoxicity: a case report. Cancer Chemotherapy and Pharmacology, 1987, 19, 87-88. | 1.1 | 1 |
| 206 | Correlations of thermal washout rate, steady state temperatures, and tissue type in deep seated recurrent or metastatic tumors. International Journal of Radiation Oncology Biology Physics, 1987, 13, 907-916. | 0.4 | 68 |
| 207 | N<sub>3</sub>(TNM-UICC) metastatic neck nodes managed by combined radiation therapy and hyperthermia: clinical results and analysis of treatment parameters. International Journal of Hyperthermia, 1986, 2, 189-200. | 1.1 | 51 |
| 208 | Local Microwave Hyperthermia in Cancer Therapy. Preliminary Report. Tumori, 1982, 68, 247-251. | 0.6 | 4 |